Pure Red Cell Aplasia after ABO-Mismatched Allogeneic Stem Cell Transplantation Treated with Therapeutic Plasma Exchange and Rituximab
Rebecca Karp(Beth Israel Deaconess Medical Center), Ayad Hamdan(University of California San Diego), David Avigan(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center), Erik J. Uhlmann(Beth Israel Deaconess Medical Center), Myrna Nahas, Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center)
Cited by 3
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k